Understanding the role of gamma secretase in a skin condition called hidradenitis suppurativa.
Official title: Dysregulation of Gamma Secretase in Common Acquired Hidradenitis Suppurativa
Funded at Johns Hopkins University · NIH-11161854 · Data updated 2026-11-12
This study is looking into hidradenitis suppurativa, a painful skin condition, to understand how a protein called gamma secretase might be affecting it, especially in people who don't have known genetic issues, with the hope of finding better treatments for those who struggle with this condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | May 15, 2025 |
| Project end | May 14, 2028 |
| Funding year | 2025 |
| Award (this year) | $53,974 |
| NIH project number | 1F30AI191436-01 |
| Project ID | NIH-11161854 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hidradenitis suppurativa, particularly those who do not have a known genetic mutation.
✕Less likely to help
Patients with hidradenitis suppurativa who have a clear genetic mutation causing their condition may not benefit from this research.
What this research studies
This research investigates hidradenitis suppurativa (HS), a chronic skin condition that causes painful lesions and scarring. The study focuses on the role of gamma secretase, a protein complex that may be dysregulated in patients with HS, particularly those without identifiable genetic mutations. By examining the immune signaling in skin cells and the factors leading to the loss of a specific protein called nicastrin, the research aims to uncover the underlying mechanisms of HS. This could lead to better understanding and potential new treatments for patients suffering from this debilitating condition.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and management strategies for patients with hidradenitis suppurativa.
How similar studies have gone: While the specific approach of this research is novel, previous studies have shown promise in understanding similar inflammatory skin conditions through the investigation of immune signaling pathways.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Minsky, Hana Bleicher — Johns Hopkins University
- Study coordinator: Minsky, Hana Bleicher
Related research
Other NIH-funded projects on the same topics.
-
Anti-CD38 immunotherapy for severe hidradenitis suppurativa
A new treatment using anti-CD38 therapy is being tested for people with severe hidradenitis suppurativa who have not responded to prior therapies.
-
Botulinum toxin blocks nerve signals to immune cells to treat hidradenitis suppurativa
This NIH grant tests a new approach to hidradenitis suppurativa by using botulinum toxin to interrupt nerve signals that may drive skin inflammation in patients.
-
Precision therapies for hidradenitis suppurativa using AI
A doctor-researcher team at UC San Francisco is using advanced computer methods to find personalized drug options to treat hidradenitis suppurativa.
-
Injectable Hydrogel for HS: a localized therapy to ease painful skin disease
A new baricitinib hydrogel is being developed to deliver pain relief and reduce inflammation directly in hidradenitis suppurativa (HS) lesions, potentially lowering systemic side effects.
-
Whole-genome sequencing to understand hidradenitis suppurativa in diverse groups
Researchers will study the genetic factors that contribute to hidradenitis suppurativa, especially in African American, Hispanic/Latino, and White patients, to better understand why some people are more affected.
-
Understanding the Genes Behind Hidradenitis Suppurativa in teens and young adults
A study to find genetic factors that contribute to hidradenitis suppurativa (HS), a painful skin condition that often starts in adolescence and affects many Black individuals.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.